Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4α MIR122 pathway

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Wei, Shengnan ^a   Zhang, Ming ^a,b   Yu, Yang ^a   Lan, Xiaoxin ^a   Yao, Fan ^a   Yan, Xin ^a   Chen, Li ^a   Hatch, Grant M ^b  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; BERBERINE; CARNITINE PALMITOYLTRANSFERASE; FASN PROTEIN, HUMAN; FATTY ACID SYNTHASE; GLUCOSE 6 PHOSPHATASE; GLUCOSE BLOOD LEVEL; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN; HNF4A PROTEIN, MOUSE; INSULIN; MICRORNA; MIRN122 MICRORNA, HUMAN; MIRN122 MICRORNA, MOUSE; PALMITIC ACID DERIVATIVE; PCK2 PROTEIN, HUMAN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); SREBF1 PROTEIN, HUMAN; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANALYSIS; ANIMAL; BLOOD; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEP-G2 CELL LINE; HUMAN; LIPID METABOLISM; LIVER; MALE; METABOLISM; MOUSE;

ACETYL-COA CARBOXYLASE; ANIMALS; BERBERINE; BLOOD GLUCOSE; CARNITINE O-PALMITOYLTRANSFERASE; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY ACID SYNTHASE, TYPE I; FATTY ACID SYNTHASES; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; GLUCOSE-6-PHOSPHATASE; HEP G2 CELLS; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; INSULIN; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; PALMITATES; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84995492614     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152097     Document Type: Article

References (37)

1. Assmann G [Lipid metabolism disorder: detection and treatment. 5: Treatment of hyperlipidemia in manifest coronary heart disease, diabetes mellitus and hypertension. National cholesterol initiative]. Fortschr Med. 1991; 109: 361–363. PMID: 1885117
2. Boussageon R, Gueyffier F, Cornu C Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence? Diabetes Metab. 2014; 40: 169–175. doi: 10.1016/j.diabet.2013.12.010 PMID: 24503191
3. Conget Donlo I, Gimenez Alvarez M [New treatments for type 2 diabetes. Much ado for nothing]. Med Clin (Barc). 2009; 132: 217–218.
4. Li W, Zhang M, Gu J, Meng ZJ, Zhao LC, Zheng YN, et al. Hypoglycemic effect of protopanaxadiol-type ginsenosides and compound K on Type 2 diabetes mice induced by high-fat diet combining with streptozotocin via suppression of hepatic gluconeogenesis. Fitoterapia. 2012; 83: 192–198. doi: 10.1016/j. fitote.2011.10.011 PMID: 22056666
5. Ansell BJ Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Curr Atheroscler Rep. 2005; 7: 29–33. PMID: 15683599
6. Isaacsohn JL, Troendle AJ, Orloff DG Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome. Am J Cardiol. 2004; 93: 49C–52C. PMID: 15178516
7. Niu CS, Chen LJ, Niu HS Antihyperglycemic action of rhodiola-aqeous extract in type1-like diabetic rats. BMC Complement Altern Med. 2014; 14: 20. doi: 10.1186/1472-6882-14-20 PMID: 24417880
8. Sladek FM, Zhong WM, Lai E, Darnell JE Jr. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. 1990; 4: 2353–2365. PMID: 2279702
9. Mogilenko DA, Dizhe EB, Shavva VS, Lapikov IA, Orlov SV, Perevozchikov AP, et al. Role of the nuclear receptors HNF4 alpha, PPAR alpha, and LXRs in the TNF alpha-mediated inhibition of human apolipoprotein A-I gene expression in HepG2 cells. Biochemistry. 2009; 48: 11950–11960. doi: 10. 1021/bi9015742 PMID: 19883121
10. Mitchell SM, Gloyn AL, Owen KR, Hattersley AT, Frayling TM The role of the HNF4alpha enhancer in type 2 diabetes. Mol Genet Metab. 2002; 76: 148–151. PMID: 12083813
11. Stoffel M, Duncan SA The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A. 1997; 94: 13209–13214. PMID: 9371825
12. Li J, Ning G, Duncan SA Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. Genes Dev. 2000; 14: 464–474. PMID: 10691738
13. Zhang M, Lv X, Li J, Meng Z, Wang Q, Chang WG, et al. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol Cell Endocrinol. 2012; 363: 122–130. doi: 10.1016/j.mce.2012.08.006 PMID: 22922125
14. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol. 2001; 21: 1393–1403. PMID: 11158324
15. Li ZY, Xi Y, Zhu WN, Zeng C, Zhang ZQ, Guo ZC, et al. Positive regulation of hepatic miR-122 expression by HNF4alpha. J Hepatol. 2011; 55: 602–611. doi: 10.1016/j.jhep.2010.12.023 PMID: 21241755
16. Oliveira KG, Malta FM, Nastri AC, Widman A, Faria PL, Santana R, et al. Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3. Med Microbiol Immunol.2015
17. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005; 438: 685–689. PMID: 16258535
18. Zhang MF, Shen YQ [Antidiarrheal and anti-inflammatory effects of berberine]. Zhongguo Yao Li Xue Bao.1989; 10: 174–176. PMID: 2816420
19. Chang W, Chen L, Hatch GM Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem Cell Biol. 2014;1–8.
20. Li XY, Zhao ZX, Huang M, Feng R, He CY, Ma C, et al. Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med. 2015; 13: 278. doi: 10. 1186/s12967-015-0629-3 PMID: 26310319
21. Li Z, Jiang JD, Kong WJ Berberine up-regulates hepatic low-density lipoprotein receptor through Rasindependent but AMP-activated protein kinase-dependent Raf-1 activation. Biol Pharm Bull. 2014; 37: 1766–1775. PMID: 25196457
22. Wang YX, Kong WJ, Li YH, Tang S, Li Z, Li YB, et al. Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation. Bioorg Med Chem. 2012; 20: 6552–6558. doi: 10.1016/j.bmc.2012.09.029 PMID: 23058107
23. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004; 10: 1344–1351. PMID: 15531889
24. Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, et al. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2015; 10: e0134172. doi: 10.1371/journal.pone. 0134172 PMID: 26252777
25. Kong WJ, Wei J, Zuo ZY, Wang YM, Song DQ, You XF, et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism. 2008; 57: 1029–1037. doi: 10.1016/j.metabol.2008. 01.037 PMID: 18640378
26. Zhao W, Xue R, Zhou ZX, Kong WJ, Jiang JD Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed Pharmacother. 2008; 62: 730–731. doi: 10. 1016/j.biopha.2008.01.007 PMID: 18337056
27. Zhao L, Jiang SJ, Lu FE, Xu LJ, Zou X, Wang KF, et al. Effects of berberine and cinnamic acid on palmitic acid-induced intracellular triglyceride accumulation in NIT-1 pancreatic beta cells. Chin J Integr Med.2014
28. Indira M, Chandrashekar P, Kattappagari KK, Chandra LP, Chitturi RT, BV RR Evaluation of salivary glucose, amylase, and total protein in Type 2 diabetes mellitus patients. Indian J Dent Res. 2015; 26: 271–275. doi: 10.4103/0970-9290.162883 PMID: 26275194
29. Svedberg J, Bjorntorp P, Smith U, Lonnroth P Free-fatty acid inhibition of insulin binding, degradation, and action in isolated rat hepatocytes. Diabetes. 1990; 39: 570–574. PMID: 2185108
30. Kroh EM, Parkin RK, Mitchell PS, Tewari M Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50: 298–301. doi: 10. 1016/j.ymeth.2010.01.032 PMID: 20146939
31. Liu L, Wang S, Cao X, Liu J Analysis of circulating microRNA biomarkers for breast cancer detection: a meta-analysis. Tumour Biol. 2014; 35: 12245–12253. doi: 10.1007/s13277-014-2533-5 PMID: 25195131
32. Xie L, Wang T, Yu S, Chen X, Wang L, Qian X, et al. Cell-free miR-24 and miR-30d, potential diagnostic biomarkers in malignant effusions. Clin Biochem. 2011; 44: 216–220. doi: 10.1016/j.clinbiochem.2010. 11.002 PMID: 21093424
33. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010; 59: 285–292. doi: 10.1016/j.metabol.2009.07.029 PMID: 19800084
34. Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One. 2011; 6: e16556. doi: 10.1371/journal.pone. 0016556 PMID: 21304897
35. Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res. 2010; 51: 1513–1523. doi: 10. 1194/jlr.M004812 PMID: 20124555
36. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006; 3: 87–98. PMID: 16459310
37. Benatti RO, Melo AM, Borges FO, Ignacio-Souza LM, Simino LA, Milanski M, et al. Maternal high-fat diet consumption modulates hepatic lipid metabolism and microRNA-122 (miR-122) and microRNA-370 (miR-370) expression in offspring. Br J Nutr. 2014 111: 2112–2122. doi: 10.1017/ S0007114514000579 PMID: 24666709